Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study
Weinstein G, O’Donnell A, Davis-Plourde K, Zelber-Sagi S, Ghosh S, DeCarli CS, Thibault EG, Sperling RA, Johnson KA, Beiser AS, Seshadri S. Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. Journal Of Alzheimer's Disease 2022, 86: 1371-1383. PMID: 35213373, PMCID: PMC11323287, DOI: 10.3233/jad-215409.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloid beta-PeptidesFemaleHumansLiver CirrhosisMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePositron-Emission TomographyTau ProteinsConceptsNon-alcoholic fatty liver diseasePrevalent non-alcoholic fatty liver diseaseFIB-4 indexFatty liver diseaseAlzheimer's disease pathologyFIB-4Liver fibrosisDisease pathologyAdvanced fibrosisLiver diseaseTau pathologyRisk factorsRelationship of NAFLDTau positron emission tomography (PET) imagingEarly Alzheimer's disease pathologyCardio-metabolic risk factorsAlcoholic fatty liver diseaseThird Generation cohortsFramingham Study participantsNon-invasive indexPositron emission tomography (PET) imagingEmission Tomography ImagingMiddle-aged adultsRegional tauLiver steatosis